Overview

Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
0
Participant gender:
Female
Summary
The purpose of this study is to evaluate the safety and immunogenicity of V505 in comparison to GARDASIL (TM)
Phase:
Phase 2
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Vaccines
Criteria
Inclusion Criteria:

- Female between 16 to 26 years old

- Has never had Pap testing or have only had normal Pap test results

- Lifetime history of 0 to 4 sexual partners

Exclusion Criteria:

- History of an abnormal cervical biopsy result; History of a positive test for HPV;
History of external genital/vaginal warts; Currently a user of any illegal drugs or an
alcohol abuser

- History of severe allergic reaction that required medical attention

- Are pregnant

- Received a marketed HPV vaccine

- Currently enrolled in a clinical trial

- Currently has (or has a history of) certain medical conditions or is currently taking
or has taken certain medications (details will be discussed at time of consent)